article thumbnail

SparkRx: The first digital therapeutic for adolescents

pharmaphorum

SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually. Designing the app.

article thumbnail

Sanofi forges $30m alliance with digital health firm DarioHealth

pharmaphorum

Originally set up with a focus on diabetes, Dario has added capabilities in hypertension, weight management, and musculoskeletal and behavioural health in the intervening years, for example by acquiring musculoskeletal wearable company Upright Technologies and digital behavioural health specialist wayForward last year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US health department backs 15 COVID-focused digital health startups

pharmaphorum

The 2022 intake companies are: Carium , which operates a telehealth platform – delivered via a patient app – that provides individualised care to patients from participating healthcare systems and links to a range of wearable devices; Clear Bill of Health (CBOH), which has developed as a COVID-19 vaccination and testing status facilitation tool; Culture (..)

article thumbnail

BI, Click Therapeutics expand collaboration to PDT for schizophrenia

pharmaphorum

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will provide additional treatment options to those living with schizophrenia. Schizophrenia is one of the 15 leading causes of disability worldwide.

article thumbnail

Cognoa preps FDA filing for digital autism diagnostic

pharmaphorum

An artificial intelligence-powered diagnostic for autism spectrum disorder (ASD), developed by Cognoa, has met all its objectives in a pivotal trial and will be filed for approval with the FDA. It’s reported that parents can often spot the early signs of developmental problems within 18 months.

article thumbnail

Changing Faces: pharma supplier, DTx, and non-profit hires from November 2022

pharmaphorum

Digital therapeutics company Cognoa, which focuses on paediatric behavioural health, announced the appointment of Dr Sharief Taraman as its new CEO. Optibrium, another software developer in the AI drug discovery space, has appointed Ian Smith as its new chief technology officer. McKinnell, Jr. to support the company’s growth.

article thumbnail

Amwell dials in deals worth $320m to buy two digital health players

pharmaphorum

US telehealth group Amwell has agreed to buy two digital health specialists – SilverCloud Health and Conversa Health – as it looks to expand its services amid a boom in virtual healthcare delivery.